膀胱内噬菌体疗法治疗泌尿生殖道感染的低免疫原性
Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.
作者信息
Letkiewicz Sławomir, Łusiak-Szelachowska Marzanna, Międzybrodzki Ryszard, Żaczek Maciej, Weber-Dąbrowska Beata, Górski Andrzej
机构信息
Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), 53-114 Wrocław, Poland.
Faculty of Health Sciences, Jan Długosz University in Częstochowa, 42-200 Częstochowa, Poland.
出版信息
Antibiotics (Basel). 2021 May 25;10(6):627. doi: 10.3390/antibiotics10060627.
Abstract
Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT.
摘要
患有慢性泌尿系统和泌尿生殖系统多重耐药细菌感染的患者接受了噬菌体疗法（PT），采用膀胱内或膀胱内及阴道内噬菌体给药。单一疗程的PT并未诱导出针对所施用噬菌体的显著血清抗体反应。虽然PT的第二个周期导致抗体水平显著升高，但仍然相当低。这些数据与一些患者取得的良好治疗效果相结合，表明这种PT模式可能是治疗泌尿生殖系统感染的有效手段，也是PT临床试验的可靠模型。
相似文献
1
Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.膀胱内噬菌体疗法治疗泌尿生殖道感染的低免疫原性
Antibiotics (Basel). 2021 May 25;10(6):627. doi: 10.3390/antibiotics10060627.
2
Antiphage activity of sera during phage therapy in relation to its outcome.噬菌体治疗期间血清的抗噬菌体活性与其治疗结果的关系。
Future Microbiol. 2017 Feb;12:109-117. doi: 10.2217/fmb-2016-0156. Epub 2016 Sep 19.
3
Intravesical Gentamicin Treatment for Recurrent Urinary Tract Infections Caused by Multidrug Resistant Bacteria.膀胱内庆大霉素治疗由多重耐药菌引起的复发性尿路感染。
J Urol. 2019 Mar;201(3):549-555. doi: 10.1016/j.juro.2018.10.004.
4
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.经尿道前列腺切除术患者治疗尿路感染的膀胱噬菌体：一项随机、安慰剂对照、双盲临床试验。
Lancet Infect Dis. 2021 Mar;21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3. Epub 2020 Sep 16.
5
Neomycin-polymyxin or gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization.新霉素-多粘菌素或庆大霉素膀胱灌注可减少清洁间歇性导尿的神经源性膀胱患者的症状性尿路感染。
J Pediatr Urol. 2019 Apr;15(2):178.e1-178.e7. doi: 10.1016/j.jpurol.2018.12.001. Epub 2018 Dec 12.
6
Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy.接受噬菌体治疗的患者对葡萄球菌MS-1噬菌体鸡尾酒的抗体产生
Front Microbiol. 2016 Oct 24;7:1681. doi: 10.3389/fmicb.2016.01681. eCollection 2016.
7
Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.裂解性噬菌体在治疗小鼠多重耐药铜绿假单胞菌败血症中的效用。
Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):360-6. doi: 10.4103/0377-4929.42511.
8
Clinical aspects of phage therapy.噬菌体疗法的临床方面。
Adv Virus Res. 2012;83:73-121. doi: 10.1016/B978-0-12-394438-2.00003-7.
9
Intravesical instillation of amikacin for treatment of a lower urinary tract infection caused by Pseudomonas aeruginosa in a dog.膀胱内灌注阿米卡星治疗犬铜绿假单胞菌引起的下尿路感染。
J Am Vet Med Assoc. 2014 Oct 1;245(7):809-11. doi: 10.2460/javma.245.7.809.
10
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.双管齐下对抗致病菌：噬菌体与抗生素联合策略。
Front Cell Infect Microbiol. 2019 Feb 18;9:22. doi: 10.3389/fcimb.2019.00022. eCollection 2019.
引用本文的文献
1
Human bladder organoids model urinary tract infection and bacteriophage therapy.人类膀胱类器官可模拟尿路感染及噬菌体治疗。
bioRxiv. 2025 Jul 30:2025.07.30.667685. doi: 10.1101/2025.07.30.667685.
2
Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.用于治疗尿路感染的噬菌体疗法：进展与未来挑战
Int Urogynecol J. 2025 May 13. doi: 10.1007/s00192-025-06136-8.
3
Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistant .噬菌体疗法：一种针对多重耐药菌感染的有前景的治疗策略
Curr Pharm Des. 2025;31(13):1007-1019. doi: 10.2174/0113816128343976241117183624.
4
Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.推进噬菌体疗法：针对细菌感染靶向治疗的安全性、有效性及未来前景的全面综述
Infect Dis Rep. 2024 Nov 28;16(6):1127-1181. doi: 10.3390/idr16060092.
5
The rise, fall, and resurgence of phage therapy for urinary tract infection.用于治疗尿路感染的噬菌体疗法的兴衰与复兴
EcoSal Plus. 2024 Dec 12;12(1):eesp00292023. doi: 10.1128/ecosalplus.esp-0029-2023. Epub 2024 Jan 11.
6
Interaction of Bacteriophages with the Immune System: Induction of Bacteriophage-Specific Antibodies.噬菌体与免疫系统的相互作用：噬菌体特异性抗体的诱导
Methods Mol Biol. 2024;2734:183-196. doi: 10.1007/978-1-0716-3523-0_12.
7
Phage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review.噬菌体疗法在尿路感染管理中的应用：一项全面的系统评价。
Phage (New Rochelle). 2023 Sep 1;4(3):112-127. doi: 10.1089/phage.2023.0024. Epub 2023 Sep 20.
8
Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.噬菌体治疗肺部感染：来自临床经验的教训和关键考虑因素。
Eur Respir Rev. 2022 Oct 5;31(166). doi: 10.1183/16000617.0121-2022. Print 2022 Dec 31.
9
Biological aspects of phage therapy versus antibiotics against serovar Typhimurium infection of chickens.噬菌体治疗与抗生素治疗针对鸡伤寒血清型感染的生物学比较。
Front Cell Infect Microbiol. 2022 Aug 4;12:941867. doi: 10.3389/fcimb.2022.941867. eCollection 2022.
10
A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.波兰噬菌体治疗单位活动的全面综述——历史、里程碑和国际认可。
Viruses. 2022 May 28;14(6):1170. doi: 10.3390/v14061170.
本文引用的文献
1
Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.噬菌体疗法抑制多重耐药尿路致病性细菌：叙述性综述。
Ann Clin Microbiol Antimicrob. 2021 Apr 26;20(1):30. doi: 10.1186/s12941-021-00433-y.
2
Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection.评估噬菌体治疗联合全身抗生素治疗葡萄球菌器械感染病例中的微生物组。
Microbiome. 2021 Apr 14;9(1):92. doi: 10.1186/s40168-021-01026-9.
3
The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections.使用噬菌体治疗和预防人工关节周围感染的理论依据。
Front Microbiol. 2020 Dec 21;11:591021. doi: 10.3389/fmicb.2020.591021. eCollection 2020.
4
Phage Therapy: Towards a Successful Clinical Trial.噬菌体疗法：迈向成功的临床试验。
Antibiotics (Basel). 2020 Nov 19;9(11):827. doi: 10.3390/antibiotics9110827.
5
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.从美国一家中心连续治疗多药耐药细菌感染的首例10例静脉注射噬菌体疗法中吸取的经验教训。
Open Forum Infect Dis. 2020 Aug 27;7(9):ofaa389. doi: 10.1093/ofid/ofaa389. eCollection 2020 Sep.
6
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.经尿道前列腺切除术患者治疗尿路感染的膀胱噬菌体：一项随机、安慰剂对照、双盲临床试验。
Lancet Infect Dis. 2021 Mar;21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3. Epub 2020 Sep 16.
7
Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy.治疗一位 60 岁肾移植受者的复发性尿路感染。噬菌体治疗的应用。
Transpl Infect Dis. 2021 Feb;23(1):e13391. doi: 10.1111/tid.13391. Epub 2020 Jul 14.
8
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients.3 例肺移植受者中噬菌体治疗的早期临床经验。
Am J Transplant. 2019 Sep;19(9):2631-2639. doi: 10.1111/ajt.15503. Epub 2019 Jul 17.
9
Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.成功辅助噬菌体治疗在囊性纤维化患者耐多药铜绿假单胞菌感染中的应用。
Infection. 2019 Aug;47(4):665-668. doi: 10.1007/s15010-019-01319-0. Epub 2019 May 17.
10
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.利用工程噬菌体治疗播散性耐药脓肿分枝杆菌感染的患者。
Nat Med. 2019 May;25(5):730-733. doi: 10.1038/s41591-019-0437-z. Epub 2019 May 8.
Zotero 插件